Literature DB >> 30696947

A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination.

Kensuke Takaoka1, Masahito Kawazu2, Junji Koya1, Akihide Yoshimi1, Yosuke Masamoto1, Hiroaki Maki1, Takashi Toya1, Takashi Kobayashi1, Yasuhito Nannya1, Shunya Arai1, Toshihide Ueno3, Hironori Ueno4, Kenshi Suzuki5, Hironori Harada6, Atsushi Manabe7, Yasuhide Hayashi8, Hiroyuki Mano3,9, Mineo Kurokawa10.   

Abstract

Although several causal genes of familial myelodysplastic syndromes (MDS) have been identified, the genetic landscape and the molecular pathogenesis are not totally understood. To explore novel driver genes and their pathogenetic significance, we performed whole-exome sequence analysis of four individuals from a familial MDS pedigree and 10 candidate single-nucleotide variants (C9orf43, CYP7B1, EFHB, ENTPD7, FAM160B2, HELZ2, HLTF, INPP5J, ITPKB, and RYK) were identified. Knockdown screening revealed that Hltf downregulation enhanced colony-forming capacity of primary murine bone marrow (BM) stem/progenitor cells. γH2AX immunofluorescent staining assay revealed increased DNA damage in a human acute myeloid leukemia (AML) cell line ectopically expressing HLTF E259K, which was not observed in cells expressing wild-type HLTF. Silencing of HLTF in human AML cells also led to DNA damage, indicating that HLTF E259K is a loss-of-function mutation. Molecularly, we found that an E259K mutation reduced the binding capacity of HLTF with ubiquitin-conjugating enzymes, methanesulfonate sensitive 2 and ubiquitin-conjugating enzyme E2N, resulting in impaired polyubiquitination of proliferating cell nuclear antigen (PCNA) in HLTF E259K-transduced cells. In summary, our results indicate that a familial MDS-associated HLTF E259K germline mutation induces accumulation of DNA double-strand breaks, possibly through impaired PCNA polyubiquitination.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30696947     DOI: 10.1038/s41375-019-0385-0

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  3 in total

1.  A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma.

Authors:  Cheng Luo; Songmao Wang; Wenjie Shan; Weijie Liao; Shikuan Zhang; Yanzhi Wang; Qilei Xin; Tingpeng Yang; Shaoliang Hu; Weidong Xie; Naihan Xu; Yaou Zhang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

2.  Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes.

Authors:  Sushree S Sahoo; Victor B Pastor; Charnise Goodings; Rebecca K Voss; Emilia J Kozyra; Amina Szvetnik; Peter Noellke; Michael Dworzak; Jan Starý; Franco Locatelli; Riccardo Masetti; Markus Schmugge; Barbara De Moerloose; Albert Catala; Krisztián Kállay; Dominik Turkiewicz; Henrik Hasle; Jochen Buechner; Kirsi Jahnukainen; Marek Ussowicz; Sophia Polychronopoulou; Owen P Smith; Oksana Fabri; Shlomit Barzilai; Valerie de Haas; Irith Baumann; Stephan Schwarz-Furlan; Marena R Niewisch; Martin G Sauer; Birgit Burkhardt; Peter Lang; Peter Bader; Rita Beier; Ingo Müller; Michael H Albert; Roland Meisel; Ansgar Schulz; Gunnar Cario; Pritam K Panda; Julius Wehrle; Shinsuke Hirabayashi; Marta Derecka; Robert Durruthy-Durruthy; Gudrun Göhring; Ayami Yoshimi-Noellke; Manching Ku; Dirk Lebrecht; Miriam Erlacher; Christian Flotho; Brigitte Strahm; Charlotte M Niemeyer; Marcin W Wlodarski
Journal:  Nat Med       Date:  2021-10-07       Impact factor: 87.241

3.  Helicase-Like Transcription Factor HLTF and E3 Ubiquitin Ligase SHPRH Confer DNA Damage Tolerance through Direct Interactions with Proliferating Cell Nuclear Antigen (PCNA).

Authors:  Mareike Seelinger; Marit Otterlei
Journal:  Int J Mol Sci       Date:  2020-01-21       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.